Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
0.090 | Biomarker | disease | BEFREE | Preliminary data indicate that recombinant C-type natriuretic peptide (CNP) is safe in children and increases growth velocity upon 42 months of treatment in achondroplasia. | 31789832 | 2020 | ||||
|
0.090 | Biomarker | disease | BEFREE | SIGNIFICANCE STATEMENT: The hormone C-type natriuretic peptide (CNP) is in clinical development for the treatment of comorbidities associated with achondroplasia, the most common form of human dwarfism. | 31235532 | 2019 | ||||
|
0.090 | Biomarker | disease | BEFREE | C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia. | 31269546 | 2019 | ||||
|
0.090 | Biomarker | disease | BEFREE | There are successes with the use of growth hormone in individuals with SHOX deficiencies, asfotase alfa in hypophosphatasia, and some promising data for c-type natriuretic peptide for those with achondroplasia. | 28808977 | 2017 | ||||
|
0.090 | Biomarker | disease | BEFREE | These results clearly demonstrate the therapeutic potential of CNP for treatment of midfacial hypoplasia and foramen magnum stenosis in achondroplasia. | 28644737 | 2017 | ||||
|
0.090 | Biomarker | disease | BEFREE | C-Type Natriuretic Peptide Analog as Therapy for Achondroplasia. | 26684019 | 2016 | ||||
|
0.090 | GeneticVariation | disease | BEFREE | Subcutaneous administration of one of these CNP variants (BMN 111) resulted in correction of the dwarfism phenotype in a mouse model of ACH and overgrowth of the axial and appendicular skeletons in wild-type mice without observable changes in trabecular and cortical bone architecture. | 25650377 | 2015 | ||||
|
0.090 | Biomarker | disease | BEFREE | A phase 2 multicenter and multinational trial is being developed to evaluate a CNP analog treatment for achondroplasia. | 25196103 | 2014 | ||||
|
0.090 | Biomarker | disease | BEFREE | We have shown that targeted overexpression of CNP in cartilage or systemic administration of CNP reverses the impaired skeletal growth of mice model of achondroplasia, the most common form of human skeletal dysplasias. | 20567091 | 2010 |